MONROVIA, Calif. & HOUSTON --(BUSINESS WIRE)--Jan. 6, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced
-- Research collaboration focused on the discovery of novel bispecific antibodies directed toward the CD28 co-stimulatory receptor and an undisclosed prostate tumor target -- -- Xencor receives $50 million upfront payment and is eligible to receive potential milestone payments and a royalty on net
MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 6, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced updated data from its ongoing Phase 1 dose-escalation study of
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 12, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at three upcoming
MONROVIA, Calif. & PLANEGG/ MUNICH, Germany & WILMINGTON, Del. --(BUSINESS WIRE)--Nov. 11, 2020-- Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of
-- XmAb20717 was generally well-tolerated; 19% objective response rate (ORR) observed across cohorts at the recommended dose level -- -- Early clinical activity, including prostate-specific antigen (PSA) reductions in patients with advanced prostate cancer, support initiation of new Phase 1b study
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 9, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb ®
-- Management to Host Conference Call at 4:30 p.m. EST Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 5, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 4, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that data from the ongoing Phase 1 dose-escalation study of
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 29, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release third quarter 2020 financial results after
